These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 29107073)

  • 21. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlations between prognosis and regional biomarker profiles in head and neck squamous cell carcinomas.
    Szentkúti G; Dános K; Brauswetter D; Kiszner G; Krenács T; Csákó L; Répássy G; Tamás L
    Pathol Oncol Res; 2015 Jul; 21(3):643-50. PubMed ID: 25547827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polyfunctionality of CD4
    Doescher J; Jeske S; Weissinger SE; Brunner C; Laban S; Bölke E; Hoffmann TK; Whiteside TL; Schuler PJ
    Strahlenther Onkol; 2018 May; 194(5):392-402. PubMed ID: 29663037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiation therapy for patients with newly diagnosed metastatic head and neck squamous cell carcinoma.
    Kabarriti R; Baliga S; Ohri N; Guha C; Kalnicki S; Garg MK
    Head Neck; 2019 Jan; 41(1):130-138. PubMed ID: 30556318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer.
    Cirauqui B; Margelí M; Quiroga V; Quer A; Karachaliou N; Chaib I; Ramírez JL; Muñoz A; Pollán C; Planas I; Drozdowsky A; Rosell R
    Tumour Biol; 2016 Oct; 37(10):13435-13443. PubMed ID: 27465548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
    Shinoto M; Shioyama Y; Sasaki T; Nakamura K; Ohura H; Toh Y; Higaki Y; Yamaguchi T; Ohnishi K; Atsumi K; Hirata H; Honda H
    Am J Clin Oncol; 2011 Aug; 34(4):362-6. PubMed ID: 20686402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
    Karakaya E; Yetmen O; Oksuz DC; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Oral Oncol; 2013 Jan; 49(1):55-9. PubMed ID: 22858313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lewis x Antigen is Associated to Head and Neck Squamous Cell Carcinoma Survival.
    Rabassa ME; Pereyra A; Pereyra L; Segal-Eiras A; Abba MC; Croce MV
    Pathol Oncol Res; 2018 Jul; 24(3):525-531. PubMed ID: 28681122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcome of seropositive HIV patients with head and neck squamous cell carcinoma treated with radiation therapy and chemotherapy.
    Mourad WF; Hu KS; Shasha D; Concert C; Ishihara D; Lin W; Gamez ME; Lukens JN; Shourbaji RA; Ryniak M; Li Z; Culliney BE; Khorsandi AS; Tran T; Jacobson A; Manolidis S; Schantz S; Urken M; Persky MS; Harrison LB
    Anticancer Res; 2013 Dec; 33(12):5511-6. PubMed ID: 24324090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic molecular markers in head and neck squamous cell carcinoma in a New Zealand population: matrix metalloproteinase-2 and sialyl Lewis x antigen.
    Gunawardena I; Arendse M; Jameson MB; Plank LD; Gregor RT
    ANZ J Surg; 2015 Nov; 85(11):843-8. PubMed ID: 24171785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
    Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
    Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.
    Sailer V; Gevensleben H; Dietrich J; Goltz D; Kristiansen G; Bootz F; Dietrich D
    PLoS One; 2017; 12(6):e0179412. PubMed ID: 28617833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region.
    Maula SM; Luukkaa M; Grénman R; Jackson D; Jalkanen S; Ristamäki R
    Cancer Res; 2003 Apr; 63(8):1920-6. PubMed ID: 12702584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chromosomal aberrations and prognosis in patients with concomitant chemoradiotherapy for resected head and neck cancer.
    Park SW; Joo YH; Jung SH; Yim SH; Nam IC; Cho KJ; Kim MS; Chung YJ
    Oncol Rep; 2016 Apr; 35(4):2207-15. PubMed ID: 26821349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer.
    Beschel LM; Leu M; Reichardt SD; Rave-Fränk M; Schirmer MA; Stadelmann C; Canis M; Wolff HA; Reichardt HM
    Oncotarget; 2016 Oct; 7(40):65902-65915. PubMed ID: 27589568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy.
    de Roest RH; Mes SW; Poell JB; Brink A; van de Wiel MA; Bloemena E; Thai E; Poli T; Leemans CR; Brakenhoff RH
    Clin Cancer Res; 2019 Dec; 25(23):7256-7265. PubMed ID: 31439582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epithelial-to-mesenchymal transition is a prognostic marker for patient outcome in advanced stage HNSCC patients treated with chemoradiotherapy.
    van der Heijden M; Essers PBM; Verhagen CVM; Willems SM; Sanders J; de Roest RH; Vossen DM; Leemans CR; Verheij M; Brakenhoff RH; van den Brekel MWM; Vens C
    Radiother Oncol; 2020 Jun; 147():186-194. PubMed ID: 32413532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistently elevated soluble MHC class I polypeptide-related sequence A and transforming growth factor-β1 levels are poor prognostic factors in head and neck squamous cell carcinoma after definitive chemoradiotherapy.
    Chen JL; Chang CC; Huang YS; Kuo HY; Chen TY; Wang CW; Kuo SH; Lin YL
    PLoS One; 2018; 13(8):e0202224. PubMed ID: 30096190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A gene signature associated with prognosis and immune processes in head and neck squamous cell carcinoma.
    Bai S; Zhang P; Zhang JC; Shen J; Xiang X; Yan YB; Xu ZQ; Zhang J; Long L; Wang C; Shi P; Yang L; Chen W; Liu H
    Head Neck; 2019 Aug; 41(8):2581-2590. PubMed ID: 30839132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of center size and experience on outcomes in head and neck cancer.
    Corry J; Peters LJ; Rischin D
    J Clin Oncol; 2015 Jan; 33(2):138-40. PubMed ID: 25488964
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.